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ABSTRACT 
Objective: Separation and identification of the process impurities in the manufacture of temsirolimus drug viz., rapamycin, temsirolimus 
regioisomer (monoester) (TS monoester), and temsirolimus diester (TS diester). 
Methods: During the process development of temsirolimus (TS), three process impurities-rapamycin, temsirolimus regioisomer (monoester) and 
temsirolimus diester-were detected by high-performance liquid chromatography (HPLC). Impurities were isolated by medium pressure liquid 
Chromatography (MPLC) and characterized by ESI-MS/MS, 1H NMR, FT-IR spectral data. 
Results: These impurities are characterised with the help of ESI MS/MS, 1H NMR, and FT-IR data. The impurities are identified and characterised as 
the process impurities. One of them is the starting material i.e. rapamycin and the other two are formed during the manufacture of the drug. This 
method offers advantages over using photodiode-array UV detection (LC-PDA) for the determination of peak purity, viz. components with similar 
UV spectra can be distinguished.  
Conclusion: The structures of these impurities were characterized as rapamycin, TS Monoester, and TS Diester. Out of these process impurities, 
rapamycin has been previously identified while the other two are previously unreported. 
Keywords: 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open-access article under the CC BY license (





The most common malignancy of the kidney and accounts for 2%-
3% of all adult cancers is renal cell carcinoma (RCC) [1]. Though 
surgical resection can be curative in localized disease, prognosis of 
advanced renal cell carcinoma is poor with a 5-years survival rate of 
5%-10%. Immunotherapy with interferon-α (IFN) has produced 
modest survival benefice in clinical trials [2-7] but high dose 
interleukin-2, though active in highly selected patients, is associated 
with toxicity [8, 9]. Since 2007 Phase III studies have emphasized the 
importance of targeting angiogenesis through vascular endothelial 
growth factor receptor (VEGFR) tyrosine kinase inhibition with 
sunitinib [10] and sorafenib [11] or direct VEGF inhibition with 
bevacizumab in combination with IFN [12, 13]. The mammalian 
target of rapamycin (mTOR), a member of the phosphatidylinositol 3 
kinase family, is a multifunctional serine-threonine kinase that acts 
as a central regulator of cell growth, proliferation, and apoptosis [14, 
15]. It modulates the expression and stability of hypoxia-inducible 
factor (HIF)-1α, which regulates expression of VEGF. Temsirolimus 
(cci-779) is a potent and selective inhibitor of mTOR. It has 
demonstrated its efficacy as first-line immunotherapy in poor 
prognosis metastatic RCC in comparison with IFN [16]. 
Temsirolimus (sirolimus-42-[2,2-bis-(hydroxymethyl)]-propionate) 
is an ester analog of rapamycin, a natural macrolide antibiotic with 
antifungal, antitumor, and immunosuppressive activities. 
Temsirolimus has demonstrated significant inhibition of tumour 
growth both in vitro and in vivo. Temsirolimus is currently in phase 
III clinical development for the treatment of renal cancer. 
The method development of a drug is very important [17] to the 
pharmaceutical industry as the development of a method is essential 
for the discovery, development, and evaluation of medicines in the 
pharmaceutical formulation. The method development and validation 
of temsirolimus is carried out by the same authors [18, 19]. 
The present study describes the identification and determination of 
three impurities rapamycin, temsirolimus regioisomer (monoester) 
(TS monoester) and temsirolimus diester (TS diester) in crude 
temsirolimus drug [20-22]. All the impurities were isolated using 
MPLC, characterized by mass spectral data and NMR, FT-IR as 
additional evidence. The impurities TS monoester and TS diester 
with hydroxyl ester moiety in the side chain appear to be novel and 
previously not reported. Impurities in active pharmaceutical 
ingredient (API) are highly undesirable and in some cases can prove 
to be harmful to the patient. The ICHQ7 and ICHQ3A are a guide for 
API manufacturers, mentions that impurities are to be maintained 
below the set limits. Thus, it is pertinent to identify and characterize 
the impurities in API to develop suitable process wherein their 
levels can be kept within permissible limits. The impurity profile 
study should be carried out for any bulk drug to identify and 
characterize all the unknown impurities that are present at a level of 
above 0.1%. A comprehensive study has been undertaken to isolate 
and characterize these impurities by chromatographic, mass 
spectral studies and NMR spectroscopic techniques. This article 
describes the separation, identification, isolation, and 
characterization of three process impurities that are present in the 
range of 0.08%-0.12% of peak area of the bulk drug of temsirolimus. 
The monitoring of these impurities is important for pharmaceutical 
drug development and quality control of drug substance. 
Molecular formula of temsirolimus is C56H87NO16
MATERIALS AND METHODS 
 and molar mass is 
1030.28. Systematic (IUPAC) name is (1R,2R,4S)-4-{(2R)-2-
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-
dihydr-oxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-
pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22, 23,24, 25,26,27,28,29,31, 32,33, 
34,34a-tetracosa-hydro-3H-23,27-epoxypyrido[2,1-c][1,4] oxazacyclo-
hentri-acontin-3-yl] propyl}-2-methoxy cyclohexyl 3-hydroxy-2-
(hydroxymethyl)-2-methyl propanoate. The molecular structure of 
temsirolimus is given in table 1. 
Reagents and chemicals 
The water used in preparing the solutions had been purified by a 
Milli-Q system (Millipore). n-hexane (HPLC grade), methanol (HPLC 
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grade) and acetonitrile (HPLC grade) were purchased from Rankem 
(Ranbaxy India). Trifluoro acetic acid (HPLC grade), acetic acid 
(HPLC grade), ethanol (HPLC grade) and ammonia (HPLC grade) 
were purchased from Sigma-Aldrich (Sigma-Aldrich Ltd). Crude 
temsirolimus drug sample was obtained from Hetero Drugs Limited 
Hyderabad, India as gift samples. 
High-performance liquid chromatography (analytical)  
A Waters HPLC system equipped with Alliances 2695 series low 
pressure quaternary gradient pump along with photodiode array 
detector and autosampler has been used for the analysis of samples. 
The data was collected and processed using Waters Empower 3 
software. The YMC PACK SIL (250 X 4.6 mm, 5 μm, YMC, America, 
Inc) column was employed for the separation of impurities from 
temsirolimus. The column eluent was monitored at 280 nm. A 
simple isocratic Normal-Phase HPLC method was optimized for the 
separation of impurities from temsirolimus active pharmaceutical 
ingredient where the mobile phase ratio was a mixture of n-hexane, 
ethanol and trifluoroacetic acid in a ratio of 90:10:0.01, v/v. 
Chromatography was performed at column oven temperature 35°C 
with a flow rate of 1.5 ml min-1
The LC-MS analysis was carried out on AB Sciex Instruments 4000 Q 
TRP Linear Ion Trap Quadrupole LC/MS/MS Mass Spectrometer 
connected with a Waters HPLC system equipped with Alliances 2695 
series with PDA detector. The YMC PACK SIL (250 X 4.6 mm, 5 μm, 
YMC, America, Inc) column was used for the separation. A simple 
isocratic reverse-phase HPLC method was optimized for the 
separation of impurities from temsirolimus active pharmaceutical 
ingredient where the mobile phase ratio was a mixture of water, 
methanol, acetonitrile, and trifluoroacetic acid in a ratio of 
15:70:15:0.01, v/v. Chromatography was performed at column oven 
temperature 35̊C at a flow rate of 1.5 m l min
, auto-sampler temperature 5 °C and 
injection volume 10 μl. The chromatographic run time was 60 min. 
Mass spectrometry (LC-MS/MS) 
-1
Isolation of impurities by MPLC 
, auto-sampler 
temperature 5 °C and injection volume 10 μl. The chromatographic 
run time was 60 min. After chromatographic separation, the mobile 
phase was directly introduced into the mass spectrometer via 
electrospray ionization (ESI) source operating in the positive and 
negative mode. Identification was performed using Q1 MS (Q1) and 
production (MS2) scan types to optimize all the mass parameters. 
The curtain gas reached 20 psi. The ion spray voltage was set at 
4500 V and temperature at 475 °C. The nebulizer gas (GS1) and 
turbo gas (GS2) were 45 and 55 psi. The declustering potential (DP) 
and entrance potential (EP) were 25 and 10 V. Data acquisition was 
carried out by analyst 1.4.2 software on a dell computer. 
Crude temsirolimus was dissolved in n-hexane and adsorbed over 
silica gel (mesh 230–400). This adsorbed compound was applied to 
MPLC (Buchi R688, column: 70 cm×460 cm, Fraction Collector Buchi 
684) using silica gel (mesh 230–400) as adsorbent and eluted with 
n-hexane-ethanol. The elution solvents were classified as (A) n-
hexane and (B) ethanol. The impurities were eluted according to the 
gradient by changing the % of (B) at the different time, T (min)/%B 
= 0/0, 15/1, 20/2.0, 30/2.5, 45/3.0, 90/4.0 at a flow rate of 50 
ml/min. Fractions of 100 ml were collected, and those exhibiting 
similar TLC profiles combined. The enriched and purified samples of 
individual impurities were provided by Hetero Drugs. 
NMR spectroscopy 
The NMR experiments were performed on Bruker spectrometers 
operating at 400 MHz in CDCl3. 1
FT-IR spectroscopy 
H chemical shift values were reported 
on the δ scale in ppm, relative to TMS (δ = 0.00) as an internal standard. 
Samples were measured as neat by using ATR on Bruker FTIR 
Spectrometer Alpha (Bruker Corporation, Germany) in the range of 
600–4000 cm−1 with 20 scans and 2 cm−1
 
 resolution. OPUS software 
version 6.5. 
 
Fig. 1: Crude temsirolimus HPLC chromatogram 
 
 
Fig. 2: Temsirolimus impurity spiked HPLC chromatogram 
 
RESULTS AND DISCUSSION 
The HPLC chromatograms of crude temsirolimus and process 
impurity spiked sample is shown in fig. 1 and 2. The LC/MS data 
gave the molecular ions of the impurities. HPLC retention time (RT) 
and the tentative structures deduced from the MS data are shown in 
table 1. Impurities were isolated using MPLC and characterized by 
NMR and FTIR spectroscopy. The structures of impurities, 
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rapamycin, TS monoester and TS diester were confirmed by the 
spectral data. The NMR data and IR & Mass data were compared 
with those of temsirolimus (table 2, 3).  
Structure elucidation of rapamycin 
Rapamycin was formed in temsirolimus drug in the manufacturing 
process as an impurity and identified as a 31-membered macrocycle 
of 15 stereo-centers and multiple functional groups, namely trans-
rotamer of 10-hemiketal. It is a starting material for temsirolimus. 
The mass spectrum of rapamycin showed an ammonium adduct 
[M+NH4]+at m/z 931.5, a protonated molecular ion [M+H]+at m/z 
914.4 and a deprotonated molecular ion [M-H]-at m/z 912.4, 
indicating that the rapamycin has a molecular mass less than that of 
temsirolimus by 116.7 Da. The deprotonated molecular ion [M-
H]+(m/z 912.4) gave m/z at 590, 437 and 261 Da on further 
fragmentation [23, 24]. These ions formation agree with the 
fragmentation pathway of the proposed structure of rapamycin. 
Further confirmation came from HPLC retention time, FT-IR (table 
3) and the 1H NMR spectrum (table 2) and comparing rapamycin 
with temsirolimus standard substance. IR spectrum displayed 
characteristic absorption at 3414.3, 1719.1 and 1644.8 cm−1 
corresponding to broad peak OH, non-conjugated C=O and 
conjugated and non-conjugated C=C stretching confirming all the 
major functional groups in rapamycin. In the 1HNMR spectrum of 
rapamycin, the chemical shift values of ester side chain signals were 
found to be absent. The 1HNMR spectrum of rapamycin (table 2) 
showed a significant change in the chemical shifts value of the 
proton in the C60 position. The C60 methyl proton signal was found 
to be absent in rapamycin while in temsirolimus, the C60 methyl 
proton signal is observed at 1.09 ppm. Another significant difference 
is observed in the 1H NMR spectrum at the C58 and C59 position. 
C58 and C59 hydroxyl proton signal was found to be absent in 
rapamycin while in temsirolimus, the C58andC59 hydroxyl proton 
signal is observed at 2.91-3.01 ppm. The 1HNMR spectrum of 
rapamycin (table 2) showed a significant change in the chemical 
shifts value of the proton at the C42 position. The C42 hydroxyl 
proton signal was found to be present in rapamycin while absent in 
temsirolimus and hydroxyl proton signal is observed at 3.59 ppm. 1H 
NMR spectrum of rapamycin confirms the positions of hydrogen 
atoms and their environment in the molecule. Based on spectral 
data, rapamycin was confirmed as a single isomeric form, namely 
trans-rotamer of 10-hemiketal. The molecular formula of rapamycin 
is C51H79NO13
 
 and molar mass is 913.43. Systematic (IUPAC) name 
is (1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 
35R)-1, 18-Dihydroxy-12 {(1R)-2-[(1S, 3R, 4R)-4-hydroxy-3-
methoxycyclohexyl]-1-methylethyl}-19, 30-dimethoxy-15, 17, 21, 
23, 29, 35-hexamethyl-11, 36-dioxa-4-azatricyclo [30.3.1.04, 9] 
hexatriaconta16, 24, 26, 28-tetraen 2,3,10, 14,20 penton. 
Table 1: Name of the compound, retention time (RT), structure and molecular weight of the impurities 







TS Regio isomer (Monoester) 33.11 
 
1030 
TS Diester 51.91 
 
1146 
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H NMR data of temsirolimus and temsirolimus process impurities 
Rapamycin Ts Monoester Ts diester 
δ (ppm) Position of proton δ (ppm) Position of proton δ (ppm) Position of proton δ (ppm) Position of proton 
0.88-0.90 47 0.92 47 0.92 47 0.92 47 
0.92-0.94 46 0.95 46 0.95 46 0.95 46 
0.96-0.98 51 0.99 51 0.99 51 0.99 51 
1.02-1.04 49 1.05 49 1.05 49 1.05 49 
1.07-1.08 50 1.08 50 1.08 50 1.08 50 
1.09 60 - - 1.12 60 1.23 60,65 
1.12-1.26 19,20,21 1.2-1.3 19,20,21 1.2-1.3 19,20,21 1.2-1.3 19,20,21 
1.45-1.46 43,10,11 1.4-1.54 43,11,10 1.4-1.54 43,11,10 1.4-1.54 43,11,10 
1.57-1.60 35,48 1.58-1.65 35,48 1.58-1.65 35,48 1.58-1.65 35,48 
1.63 44,38 1.60-1.87 44,38 1.60-1.87 44,38 1.60-1.87 44,38 
1.73 45 1.76 45 1.76 45 1.76 45 
2.03-2.06 26,8,12 1.95-2.09 8,12 1.95-2.09 8,12 1.95-2.09 8,12 
2.13-2.15 31-OH 2.81-2.89 31-OH - - - - 
2.30-2.34 34,36 2.10-2.59 26,34,36 2.10-2.59 26,34,36 2.10-2.59 26,34,36 
2.58-2.59 39,37 2.39,2.70 37,39 2.39,2.70 37,39 2.39,2.70 37,39 
2.67-2.73 40 2.79 40 2.79 40 2.79 40 
2.91-3.01 58,59-OH - - 2.91-3.05 58,59-OH 2.91-3.05 63,64,58,59-OH 
3.12 53 3.14 53 3.14 53 3.14 53 
3.28-3.37 39,28,18 3.17-3.47 18,28 3.17-3.47 18,28 3.17-3.47 18,28 
3.31 54 3.33 54 3.33 54 3.33 54 
3.34 52 3.35 52 3.35 52 3.35 52 
- - 3.59 55-OH 3.93 55-OH - - 
3.57-3.85 58,59,41,32,7,9 3.55-3.88 41,7,32,9 3.55-3.88 58,59,41,7,32, 9 3.55-3.88 63,64,58,59,41,7,3, 2,9 
4.16-4.19 25 4.18 25 4.18 25 4.18 25 
4.68-4.74 42 4.71 42 4.71 42 4.71 42 
4.78 13-OH 4.78 13-OH 4.78 13-OH 4.78 13-OH 
5.14-5.17 22 5.11 22 5.11 22 5.11 22 
5.38-5.41 31 5.27 31 5.27 31 5.27 31 
5.46-5.55 29,1 5.40-5.56 29,1 5.40-5.56 29,1 5.40-5.56 29,1 
5.93-5.96 5 5.69-5.99 5 5.69-5.99 5 5.69-5.99 5 
6.09-6.15 2 6.11-6.13 2 6.11-6.13 2 6.11-6.13 2 
6.18-6.40 3,4 6.29-6.39 3,4 6.29-6.39 3,4 6.29-6.39 3,4 
 
Table 3: FT-IR and mass spectral data of temsirolimus and impurities (rapamycin, TS monoester and TS diester) 





3414(OH stretching), 2966(aliphatic C-H stretching), 1719(C=O 
stretching), 1644(C=C aromatic stretching), 1449(N-H bending), 
1383(aliphatic C-H stretching), 1280, 1103(C-O stretching), 1199(C-N 
stretching) and 756 (aromatic C-H bending). 
+ve ES-MS: 914 (M+H)+, 931 (M+NH4)+, 
936 (M+Na)+, 952 (M+K)+;-ve ES-MS: 912 
(M-H)-, 947 (M+Cl)-. 
2  
TS monoester 
3376(OH stretching), 2961(aliphatic C-H stretching), 1718(C=O 
stretching), 1641(C=C aromatic stretching), 1459(N-H bending), 
1378(aliphatic C-H stretching), 1262, 1101(C-O stretching), 1198(C-N 
stretching) and 809 (aromatic C-H bending). 
+ve ES-MS: 1031(M+H)+, 1048 
(M+NH4)+, 1053 (M+Na)+, 1069 (M+K)+;-





3456(OH stretching), 2935(aliphatic C-H stretching), 1726(C=O 
stretching), 1640(C=C aromatic stretching), 1456(N-H bending), 
1392(aliphatic C-H stretching), 1291, 1108(C-O stretching), 1198(C-N 
stretching) and 716 (aromatic C-H bending). 
+ve ES-MS: 1148 (M+H)+, 1165 
(M+NH4)+, 1170 (M+Na)+, 1186 (M+K)+
-ve ES-MS: 1146 (M)
;  






3454(OH stretching), 2965(aliphatic C-H stretching), 1721(C=O 
stretching), 1644(C=C aromatic stretching), 1453(N-H bending), 
1392(aliphatic C-H stretching), 1288, 1103(C-O stretching), 1193(C-N 
stretching) and 740 (aromatic C-H bending). 
+ve ES-MS: 1031(M+H)+, 1048(M+NH4)+, 
1053(M+Na)+, 1069(M+K)+;-ve ES-MS: 
1029 (M-H)-, 1064(M+Cl)-. 
 
Structure elucidation of TS monoester 
This impurity TS Monoester was formed in temsirolimus drug 
during the manufacturing process and identified as 31-membered 
macrocycle of 15 stereo-centers and multiple functional groups, 
namely temsirolimus regioisomer. This is a hydroxyl ester at the 31 
positions of rapamycin. The ESI mass spectrum of TS monoester 
showed an ammonium adduct [M+NH4]+at m/z 1047.6 and sodium 
adduct [M+Na]+at m/z 1052.6, a protonated molecular ion [M+H]+at 
m/z 1031.4 and a deprotonated molecular ion [M-H]+at m/z 
1029.37, which is like temsirolimus. TS monoester gave two 
fragment ions at m/z 590 (A) and m/z 437 (B) in the MS/MS 
experiment [23, 24]. These two ions resulted from the cleavage of 
the C31/C32 bond and the O24/C25 ester bond. These characteristic 
cleavages are also observed in rapamycin and temsirolimus with the 
loss of neutral species, such as H2O, MeOH, and/or CO2. B ion further 
generated the fragment ions of m/z 407, m/z 389 and m/z 371 and 
ion A produced the fragment ions of m/z 546, m/z 528, m/z 514, 
and m/z 496. Further cleavage of A ion at C8/C9 and C35/C36 
(allylic cleavage) followed by loss of methanol gave fragment ions at 
m/z 261, m/z 229 and m/z 147. β-Cleavage of C33 ketone produced 
the fragment ion of m/z 101 [23, 24]. The ion at m/z 252 was 
formed by C8/C9 cleavage followed by CO2 loss (cleavage at 
C22/C23) in the left region of the A ion. The ion m/z 234 resulted 
from a further loss of H2O. Additional fragment ions at m/z 168 and 
m/z 128 arose from cleavages occurring at C13/C15 and C23/O24 
and cleavage of the amide bond (C16/N17) respectively. These ions 
(m/z 252, m/z 234, m/z 168, and m/z 128) from the left region of 
the A ion. This fragmentation pattern is also found to be same as 
temsirolimus fragmentation [23, 24]. A significant difference is 
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observed in the 1H NMR spectrum (table 2) and HPLC retention time 
of TS monoester with respect to temsirolimus. This shows that the 
TS monoester could be an isomer of temsirolimus. These fragment 
ions agree with the fragmentation pathway of the proposed 
structure of TS monoester. Further confirmation came from HPLC 
retention time, FT-IR spectrum (table 3) and 1H NMR spectrum 
(table 2) and comparing TS monoester with temsirolimus standard 
substance spectral data. IR spectrum displayed characteristic 
absorption at 3375.9, 1718.5 and 1641.42 cm−1 corresponding to 
broad peak OH, non-conjugated C=O and conjugated and non-
conjugated C=C stretching. Therefore, infrared spectrum of the 
compound confirms all the major functional groups presented in the 
TS monoester. 1H NMR spectrum of TS monoester (table 2) showed a 
significant change in the chemical shift value of the proton at the C31 
position. C31 hydroxyl proton signal was found to be absent in TS 
Monoester while in temsirolimus, the C31 hydroxyl proton signal is 
observed at 2.13-2.15 ppm. Another significant difference is 
observed in the chemical shift value of the proton at the C42 
position. The C42 hydroxyl proton signal was found to be present in 
TS monoester while absent in temsirolimus, the C42 hydroxyl 
proton signal is observed at 3.93 ppm. 1HNMR spectrum of TS 
monoester confirms the positions of hydrogen atoms and their 
environment in the molecule. Based on spectral data, TS monoester 
is confirmed as regio isomeric form of temsirolimus. Molecular 
formula of TS monoester is C56H87NO16
Structure elucidation of TS diester 
 and molar mass is 1030.29. 
Systematic (IUPAC) name is (3S, 6R, 7E, 9R, 10R, 12R, 14S, 15E, 17E, 
19E, 21S, 23S, 26R, 27R, 34aS)-27-hydroxy-3{(2R)-1-[(1S, 3R, 4R)-4-
hydroxy-3-methoxycyclohexyl]propan-2-yl}-10, 21-dimethoxy 6, 8, 
12, 14, 20, 26-hexamethyl-1,5,11,28,29-pentaoxo 1, 4, 5, 6, 9, 10, 11, 
12, 13, 14, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 34a-
tetracosahydro-3H-23,27-epoxypyrido-[2,1-c][1,4]oxazacyclo-hen-
triacontin-9-yl-3-hydroxy-2-(hydroxymethyl)-2-methyl propanoate. 
TS diester is yet another impurity formed during the manufacture of 
temsirolimus drug and it is identified as 31-membered macrocycle 
of 15 stereo-centers and multiple functional groups with a hydroxyl 
ester process impurity for temsirolimus for the 31 position. The 
mass spectrum of TS diester showed an ammonium adduct 
[M+NH4]+m/z 1164.7, a protonated molecular ion [M+H]+m/z 
1148.1 and a deprotonated molecular ion [M-H]-at m/z 1145.5 in ES 
negative mode, indicating that the TS Diester has molecular mass 
more than that of temsirolimus by 116.5 Da. Hence the TS diester is 
an ester of temsirolimus. TS diester exhibited a molecular ion at m/z 
1146.5 in the negative ESI MS spectrum. TS diester on fragmentation 
gave two important ions at m/z 590 (A) and m/z 437 (B) in the 
MS/MS experiment. These characteristic cleavages were also 
observed in rapamycin, TS monoester and temsirolimus with the 
loss of neutral species, such as H2O, MeOH, and/or CO2 [23,24]. B 
ion on fragmentation generated ions of m/z 407, m/z 389, and m/z 
371. The A ion produced fragment ions of m/z 546, m/z 528, m/z 
514, and m/z 496. This same fragmentation pattern was found in 
temsirolimus [23,24] also. This indicates that TS diester could be an 
ester of temsirolimus. A significant difference is observed in the 1H 
NMR spectrum (table 2) of TS diester with respect to temsirolimus. 
Further confirmation was given by the HPLC retention time, FT-IR 
(table 3) and 1H NMR spectrum (table 2) and comparing TS 
monoester with temsirolimus standard substance. IR spectrum 
displayed characteristic absorption at 3453.6, 2965.6, 2934.7 1721.0 
and 1644.4 cm−1 corresponding to broad peak O-H stretching, 
aliphatic C-H stretching, non-conjugated C=O and conjugated and 
non-conjugated C=C stretching. These infrared spectral values 
confirm the major functional groups presented in the TS diester. 1H 
NMR spectrum of TS monoester (table 2) showed a 1H chemical 
shifts value of the proton at the C31 position. This C31 hydroxyl 
proton signal was absent in TS diester. In temsirolimus, the C31 
hydroxyl proton signal is observed at 2.13-2.15 ppm. Another 
significant difference is observed in the 1H chemical shifts value of 
the proton at the C65 position. The C65 methyl proton signal was 
found to be present in TS diester while absent in temsirolimus. C65 
methyl proton signal is observed at 1.23 ppm. One more significant 
difference is observed in the 1H chemical shifts value of the proton at 
the C63 and C64 position. The C63 andC64 hydroxyl proton signal 
was found to be present in TS diester which is absent in 
temsirolimus. C63andC64 hydroxyl protons signal are observed at 
2.91-3.05 ppm. Another difference is observed in the chemical shifts 
value of the proton at the C42 position also. The C42 hydroxyl 
proton signal is found to be absent in TS diester while in TS 
monoester the C42 hydroxyl proton signal is observed at 3.93 ppm. 
One another significant difference is observed in the 1H chemical 
shifts value of the proton at the C63 and C64 position. The C63 
andC64 methyl proton signal was found to be present in TS diester 
while absent in TS. In TS diester C63andC64 methyl proton signal is 
observed at 3.55-3.88 ppm. 1H NMR spectrum of TS diester confirms 
the remaining hydrogen atoms and their environment in the 
molecule. Based on spectral data, TS diester is confirmed as hydroxyl 
ester of temsirolimus. A molecular formula of TS diester is 
C61H95NO19
CONCLUSION 
 and molar mass is 1146.40. Systematic (IUPAC) name is 
(1R, 2R, 4S)-4-{(2R)-2-[(3S, 6R, 7E, 9R, 10R, 12R, 14S, 15E, 17E, 19E, 
21S, 23S, 26R, 27R, 34aS)-27-hydroxy-9-{[3-hydroxy-2-
(hydroxymethyl)-2-methylpropanoyl] oxy}-10, 21-dimethoxy-6, 8, 
12, 14, 20, 26-hexamethyl-15, 11, 28, 29-pentaoxo-1, 4, 5, 6, 9, 10, 
11, 12, 13, 14, 21, 22,23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 34a-
tetracosahydro-3H-23, 27-epoxypyrido[2, 1-c][1,4] oxazacyclo-
hentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-
(hydroxymethyl)-2-methyl propanoate. 
Temsirolimus (sirolimus-42-[2,2-bis-(hydroxymethyl)]-propionate) is 
an ester analog of rapamycin, a natural macrolide antibiotic with 
antifungal, antitumor, and immunosuppressive activities. The present 
research work describes a HPLC method for detection, separation of 
three process related impurities from temsirolimus and MPLC method 
for isolation of these impurities from the temsirolimus bulk drug. All 
the three impurities detected, were characterized with the help of LC-
MS/MS, FT-IR and NMR experimental data but mainly depends on 
their retention times in chromatography. Of these three process 
impurities, one impurity rapamycin was previously known, while 
other two process impurities were found to be novel and were 
characterized as temsirolimus regioisomer (monoester) and 
temsirolimus diester in this study. 
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